Capricor Therapeutics announced that Capricor’s proprietary StealthX exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX vaccine, subject to regulatory approval. NIAID’s Division of Microbiology and Infectious Diseases would oversee the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CAPR:
- Capricor initiated with an Overweight at Cantor Fitzgerald ahead of Phase 3 data
- Capricor Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
- Capricor Therapeutics announces continuation of Phase 3 HOPE-3 trial